Early eye changes after first injection for diabetic macular edema
Part of Eyes & vision clinical trials.
This study looks at how the eyes of people with diabetes-related swelling in the retina change after their very first anti-VEGF injection. By measuring early changes in OCT scans, doctors hope to learn more about how well the treatment works and how to predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetes and swelling in the center of your retina (back of the eye).
- You have never had an eye injection, laser, or eye surgery before.
- Your eye is clear enough for the doctor to take a good picture of the retina.
- You do not have other eye diseases like glaucoma, inflammation, or age-related macular degeneration.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This study follows patients with diabetic eye swelling (a complication of diabetes affecting the macula, the part of your eye needed for detailed vision) who are receiving anti-VEGF injections—a standard treatment that reduces abnormal blood vessel growth. Researchers will measure how well your retina (the light-sensitive tissue in your eye) recovers and functions over time.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
Hear when a new Early OCT Biomarker Changes in Response to Anti-VEGF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.